07:59 Tue 29 Dec 2020
SkinBioTherapeutics - Result of AGM
SkinBioTherapeutics plc
Results of AGM
SkinBioTherapeutics plc's (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
| Resolution | For & Discretionary | Against | Withheld | |||
| | | Number of votes | % | Number of votes | % | Number of votes |
| 01 | Ordinary resolution to receive and adopt the 2020 Financial Statements | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
| 02 | Ordinary resolution to re-appoint | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
| 03 | Ordinary resolution to re-elect | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
| 04 | Ordinary resolution to re-elect | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
| 05 | Ordinary resolution to re-elect Dr | 56,163,552 |
100.00%
| Nil | 0.00% | Nil |
| 06 | Ordinary resolution to re-elect | 56,140,652 | 99.96% | 22,900 | 0.04% | Nil |
| 07 | Ordinary resolution to authorise the directors to allot shares | 56,107,097 | 99.90% | 22,900 | 0.04% | 33,555 |
| 08 | Special resolution to authorise the directors to disapply pre-emption rights | 55,896,449 | 99.52% | 37,294 | 0.07% | 229,809 |
| 09 | Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment | 55,897,801 | 99.53% | 35,942 | 0.06% | 229,809 |
For more information please contact:
| SkinBioTherapeutics plc | Tel: +44 (0) 161 468 2760 |
| | |
| Cenkos Securities plc (Nominated Adviser & Broker) | Tel: +44 (0) 20 7397 8900 |
| | |
| Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
| |
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
